"152811-62-6"@en . . . . . . . . . "Humans and other mammals"@en . "Piboserod"@en . . . . . . . . . . . . . . . . "# Darblade B, Behr-Roussel D, Gorny D, Lebret T, Benoit G, Hieble JP, Brooks D, Alexandre L, Giuliano F: Piboserod (SB 207266), a selective 5-HT4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle. World J Urol. 2005 Jun;23(2):147-51. Epub 2005 May 18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15902472 # Armstrong SR, McCullough JL, Beattie DT: Measurement of 5-HT4 receptor-mediated esophageal responses by digital sonomicrometry in the anesthetized rat. J Pharmacol Toxicol Methods. 2006 May-Jun;53(3):198-205. Epub 2005 Sep 15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16168678"@en . . "Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist."@en . . "Piboserod appears to act as a specific antagonist of one of the receptors for 5-hydroxytryptamine, the 5-HT4 receptor. The 5-HT4 receptor antagonists are thought to antagonize both the ability of serotonin to sensitize the peristaltic reflex and 5-HT-induced defecation, at least in animal studies. As 5-HT4 receptors are present in human atrial cells and when stimulated may cause atrial arrhythmias, piboserod was under investigation in clinical trials for atrial fibrillation."@en . . . . "For the treatment of atrial fibrillation and irritable bowel syndrome (IBS)."@en . . "investigational"@en . . . .